BioSpace News Archive

Aviceda Therapeutics announced today that it has dosed the first patient in Part 2 of the Phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that the Company has signed the Working with Cancer Pledge.

Surmodics, Inc. today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending September 30, 2024.

Dyne Therapeutics, Inc today announced that management is scheduled to present at the following investor conferences in February: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference , fireside chat on Thursday, February 8, 2024 at 11:00 a.m. ET.

Panavance Therapeutics Inc. today announced publication of positive data in the peer-reviewed Anti-Cancer Drugs in an article titled, “Antineoplastic Activity of GP-2250 In Vitro and in Mouse Xenograft Models.”

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB), completion by the FDA of both a Bioresearch Monitoring (BIMO) inspection of Abeona and the BLA mid-cycle review meeting.

Purple Biotech Ltd. today announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment of head and neck cancer based on its Phase 1/2 dose escalation study (NCT04474470).

Revive Therapeutics Ltd. announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.

Graviton Bioscience along with other therapeutic compounds, announces a strategic investment from Sanofi.

Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, will release findings today at AF Symposium from the recent study Ablation of Non-Pulmonary Vein Atrial Fibrillation Drivers Identified by Machine Learning in Addition to Pulmonary Vein Isolation Improves Procedural Outcomes.